Medicon Valley Alliance, together with member company Bioneer, have the pleasure to invite you to the Medicon Valley Alliance R&D Network meeting focusing on Biologics Development and Manufacturing on the 9th of May, 2022.
Biologics have paved the way for new treatment paradigms. Dominated by protein and antibody therapeutics, the biologics market now accounts for nearly 20% of the global pharmaceutical market and it continues to grow with the rise of chronic diseases, a rapidly aging population, and the entry of innovative therapies. As this field grows, new insights into streamlining protein expression, process development, and manufacturing will be key in helping bring biologics to market.
In this MVA R&D network meeting we would like to invite you to hear from speakers in academia and industry who will share their latest developments and insights to help overcome the challenges of taking biologics from idea to active pharmaceutical ingredient.
Date: 9th of May, 2022
Time: 14.30 – 18.00
Venue: Medicon Valley Alliance, Auditorium, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen
Host: Bioneer
PROGRAM:
Moderator: Christian Clausen, Chief Scientific officer, Bioneer
| 14.30 – 15.00 | Registration and arrival |
| 15.00 – 15.10 | Welcome and introduction Sofia Norås, Project Manager Networks and events, Medicon Valley Alliance Christian Clausen, Chief Scientific officer, Bioneer |
| 15.10 – 15.15 | Intellectual Property Protection for Biologics Marielle Dejligbjerg, Partner, European Patent Attorney, Høiberg |
| 15.15 – 15.45 | Keynote speaker – Optimizing Protein Production: Glycosylation, Titer and Development Bjørn Voldborg, Head of National Biologics Facility, DTU |
| 15.45 – 16.00 | Cell line and upstream mAb process development utilizing platform processes Søren Kofoed Rasmussen, Principal Scientist Process Development, Symphogen |
| 16.00 – 16.15 | Higher order structure (HOS) assessment of final protein product Björn Walse, CEO SARomics Biostructures |
| 16.15 – 16.30 | Short Break |
| 16.30 – 16.45 | Cost effective, single-use platform technology for affinity purification in the biopharmaceutical industry Jan Kyhse-Andersen, CEO, Chreto ApS |
| 16.45 – 17.00 | An AI immunology platform Anders Bundgård Sørensen, Director Research and Discovery, Evaxion Biotech |
| 17.00 – 17.15 | Optimizing expression and purification of early protein product at Bioneer A/S Christian Clausen, Chief Scientific officer, Bioneer |
| 17.15 – 17.30 | Q&A and Concluding remarks |
| 17.30 – 18.00 | Networking |
Deadline for registration is 4th of May
For more information please contact Sofia Norås sn@mva.org
The MVA R&D Network
The Medicon Valley Alliance R&D Network is a professional and social network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The network focuses on sharing best practice and experiences, as well as discussing current challenges for industry-academia collaboration and the commercialization of R&D in the Medicon Valley region, such as how we can strengthen collaboration and knowledge-sharing between academia and industry to stimulate start-up, scale-up, commercialization and growth and wat is required to turn great science into successful innovations.
Joining the network is free of charge but is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate the relevance in joining the network. For more information please contact Sofia Norås sn@mva.org
| Host | Sponsor of the event |
 |
 |
| MVA R&D Network is managed by | In collaboration with | |
|
|
 |
 |
